Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives

Contraception

Volumn 49, Issue 6, 1994, Pages 579-592

  Fruzzetti, Franca ^a   Ricci, Cabiria ^a   Fiorett, Piero ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

coagulation system; ethinylestradiol; fibrinopeptide A; Oral contraception; smoking

Indexed keywords

ANTITHROMBIN III; ESTROGEN; ETHINYLESTRADIOL; FIBRINOPEPTIDE A; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; ITALY; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; SMOKING;

BEHAVIOR; BIOLOGY; BLOOD COAGULATION EFFECTS; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, ESTROGEN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, FEMALE--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS; CORRELATION STUDIES; DEVELOPED COUNTRIES; ETHINYL ESTRADIOL--ADMINISTRACTION AND DOSAGE; ETHINYL ESTRADIOL--PHARMACODYNAMICS; EUROPE; FAMILY PLANNING; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; ITALY; MEDITERRANEAN COUNTRIES; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, LOW-DOSE; PHYSIOLOGY; RESEARCH REPORT; SMOKING--SIDE EFFECTS; SOUTHERN EUROPE; STATISTICAL STUDIES; STUDIES;

ADOLESCENT; ADULT; ANTITHROMBIN III; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; FIBRINOGEN; FIBRINOPEPTIDE A; HEMOSTASIS; HUMANS; MIDDLE AGED; PROTHROMBIN TIME; SMOKING;

EID: 0028361449     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(94)90099-X     Document Type: Article

References (37)

1. Risks and mechanisms of cardiovascular events in users of oral contraceptives
2. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report
3. Thromboembolic disease and the steroidal content of oral contraceptives: A report to the Committee on Safety of Drugs
4. Oral contraceptive use in older women and fatal myocardial infarction
5. Risk of vascular disease in women
6. Myocardial infarction and cigarette smoking in women younger than 50 years of age
7. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes
8. Smoker's heart
9. Effects of nicotine on cardiac prostaglandin and platelet thromboxane synthesis
10. Cigarette smoking inhibits prostacyclin formation
11. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes
12. Effects of changes in smoking and other characteristics on clotting factors and in the risk of ischemic heart disease
13. Smoking and plasma fibrinogen
14. Oral contraceptives smoking and risk of myocardial infarction in young women
15. Oral contraceptives clotting factors and thrombosis
16. Clinical aspects of the relationship between oral contraceptives and the hemostatic system relation to the development of cardiovascular disease
17. Oral contraceptives lipids and cardiovascular disease
18. The varying effects of progestins on lipid levels and cardiovascular disease
19. Clinical aspects of the relation between oral contraceptives abnormalities in carbohydrate metabolism and the development of cardiovascular disease
20. Effects of oral contraceptives on carbohydrate metabolism
21. Blood pressure and contraceptive use
22. Haemostatic lipid and blood pressure profiles of women on oral contraceptives containing 50 mcg or 30 mcg estrogen
23. AT III content and antithrombin III activity in oestrogen-progestogen and progestogenonly treated women
24. Oral contraceptives and venous thromboembolic disease The effect of the estrogen dose
25. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 mcg ethinylestradiol a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors
26. Comparative studies of 30 mg ethinylestradiol combined with gestodene and desogestrel on blood coagulation fibrinolysis and platelets
27. Fibrinopeptide A plasma levels during low-dose oral contraceptive treatment
28. Measurement of fibrinopeptide A in human blood
29. Potential use of fibrinopeptide A measurements in the diagnosis and management of thrombosis
30. Radioimmunoassay of fibrinopeptide A Clinical applications
31. Significance of plasma fibrinopeptide A in patients with malignancy
32. Fibrinogen to fibrin transformation
33. Pathophysiology and clinical aspects of disseminated intravascular coagulation
34. Coagulation activities of platelets in coronary artery disease
35. Long-term treatment with combined oral contraceptives and cigarette smoking associated with impaired activity of tissue plasminogen activator